Post-essential thrombocythemia myelofibrosis Trials in New York, United States
Conditions / Post-essential thrombocythemia myelofibrosis / New York, United States
Post-essential thrombocythemia myelofibrosis is a medical condition with active clinical research programs worldwide.
20 total trials for this combination
Showing top 10 of 20 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | TERMINATED | PHASE3 |
| NCT03165734 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | ACTIVE_NOT_RECRUITING | — |
| NCT03165734 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | ACTIVE_NOT_RECRUITING | — |
| NCT03165734 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | ACTIVE_NOT_RECRUITING | — |
| NCT05320198 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | RECRUITING | — |
| NCT03165734 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | ACTIVE_NOT_RECRUITING | — |
| NCT04173494 | A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) | COMPLETED | PHASE3 |
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | TERMINATED | PHASE3 |
| NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | TERMINATED | PHASE3 |
| NCT04603495 | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | ACTIVE_NOT_RECRUITING | PHASE3 |